Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level908 active trials14 approved drugs17 evidence items
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,123 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (459)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06166576 | Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis(RESOLVE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06178198 | Radiation Major Hepatectomy to Selectively Treat Large Unifocal Hepatocellular Carcinoma(RESCUE) | recruiting | Phase 2 | 30 | Seoul National University HospitalOTHER | 1 |
| Aug 20, 2026 |
| clinicaltrials |
| NCT06773845 | Building Evidence for Ablative Internal Radiation Therapy in Localized HCC Beyond the Up-To-7 Criteria(BEAT-UT7) | recruiting | Phase 2 | 100 | Seoul National University HospitalOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07608458 | Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy | not yet recruiting | N/A | 70 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT06084884 | A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma(ATHENA) | active not recruiting | Phase 1 / Phase 2 | 94 | AstraZenecaINDUSTRY | 3 | Aug 19, 2026 | clinicaltrials |
| NCT07636785 | A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors(SPKTAHC) | recruiting | Phase 1 / Phase 2 | 111 | VM Discovery, Inc.INDUSTRY | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774247 | Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma(AB-TCZ) | not yet recruiting | Phase 2 | 51 | CHA UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06764316 | A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancer(BANTAM-01) | recruiting | Phase 1 | 148 | BayerINDUSTRY | 9 | Aug 18, 2026 | clinicaltrials |
| NCT06944483 | Same-day Radioembolization for Large HCC(ISTAR-01) | recruiting | — | 138 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06979219 | Streamlining Radioembolization for Small HCC(ISTAR-02) | recruiting | — | 146 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07043387 | Streamlining Radioembolization for CCC and Metastatic Liver Cancer(ISTAR-03) | recruiting | — | 60 | Seoul National University HospitalOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07620574 | Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | enrolling by invitation | Phase 3 | 5,000 | ExelixisINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07727759 | CT Volumetry and Hepatic Vascular Deformation Mapping to Predict Post-Hepatectomy Liver Failure(BEYOND-SIZE) | recruiting | — | 1,070 | Minia UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04891289 | Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery | recruiting | Phase 2 | 164 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07070362 | Digital Early Warning System for Acute Lung Injury in Liver Surgery | recruiting | — | 3,000 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07166406 | Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | recruiting | Phase 3 | 226 | NRG OncologyOTHER | 2 | Aug 17, 2026 | clinicaltrials |
| NCT07209813 | GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma | recruiting | Phase 2 | 48 | Beijing Gene Key Life Technology Co., LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07768085 | Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT | not yet recruiting | N/A | 40,000 | Shengjing HospitalOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03847428 | Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment(EMERALD-2) | active not recruiting | Phase 3 | 908 | AstraZenecaINDUSTRY | 24 | Aug 14, 2026 | clinicaltrials |
| NCT04221893 | Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers | recruiting | N/A | 28 | University of California, San FranciscoOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT04550481 | Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study | active not recruiting | Phase 2 | 35 | Northwestern UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07764835 | Prospective Evaluation of Hepatocellular Carcinoma Surveillance in At-Risk Patients (Screening HCC)(Screening HCC) | not yet recruiting | — | 300 | D'Or Institute for Research and EducationOTHER | 0 | Aug 14, 2026 | clinicaltrials |
| NCT07765433 | Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer | not yet recruiting | Phase 2 / Phase 3 | 336 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Aug 14, 2026 | clinicaltrials |
| NCT05211323 | A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer | active not recruiting | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT05701488 | SIRT With Tremelimumab and Durvalumab for Resectable HCC | active not recruiting | Phase 1 | 20 | Jiping Wang, MD, PhDOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06618300 | Streamlined Resin Y90 Radiation Segmentectomy for Small HCC(One&Done) | active not recruiting | — | 30 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06795022 | First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours(RHEA-1) | recruiting | Phase 1 / Phase 2 | 304 | AstraZenecaINDUSTRY | 7 | Aug 13, 2026 | clinicaltrials |
| NCT07053072 | PD-1 mRNA LNP Vaccine for Advanced Primary Hepatocellular Carcinoma. | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07763301 | YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04965454 | Evaluation of Treatment Predictors Reflecting Beta-catenin Activation in Hepatocellular Carcinoma(ExTRACT-HCC) | recruiting | Phase 2 | 80 | Queen's Medical CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06549829 | the Effect of Nutrition-optimized Prehabilitation on Perioperative Intervention in Primary Liver Carcinoma | recruiting | N/A | 120 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760012 | 68Ga-SorB PET/CT Imaging in Patients With Solid Tumors(SORB-PET) | recruiting | N/A | 50 | Peking University Third HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07760038 | Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury | recruiting | N/A | 30 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07761286 | Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 288 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT06880523 | STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma(SLIDE-HCC) | recruiting | Phase 2 | 140 | Canadian Cancer Trials GroupNETWORK | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06899152 | HepQuant: Study to Assess the Role of Blood-based Biomarkers and Quantitative MR Imaging for Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | recruiting | N/A | 40 | Montefiore Medical CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06904183 | Lenvatinib, Sintilimab, and DEB-TACE With/Without HAIC for HCC >7 cm With PVTT | recruiting | Phase 2 | 320 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT03859128 | Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection(JUPITER 04) | active not recruiting | Phase 2 / Phase 3 | 427 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03959800 | Molecular Basis of Pediatric Liver Cancer | recruiting | — | 1,600 | University of PittsburghOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07159048 | The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tumors | recruiting | N/A | 120 | Fudan UniversityOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07751783 | Development and Dissemination of Exercise Prescription and Intervention for Cancer Populations | recruiting | N/A | 150 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04715191 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | recruiting | Phase 1 | 24 | Baylor College of MedicineOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05600933 | Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment | enrolling by invitation | — | 1,200 | National Cancer Institute (NCI)NIH | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07010315 | Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention | recruiting | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749859 | SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 | 80 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT02519348 | A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma | active not recruiting | Phase 2 | 433 | MedImmune LLCINDUSTRY | 9 | Aug 5, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06160752 | Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations(SURF201) | active not recruiting | Phase 1 | 40 | Tyra Biosciences, IncINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials